Hawaiian
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Nā Māhele Huahana
Nā Huahana Hōʻikeʻike
ʻO nā papa ʻo Lenopril e hoʻoikaika ana i ke kaomi koko a me ke olakino cardiovascular

ʻO nā papa ʻo Lenopril e hoʻoikaika ana i ke kaomi koko a me ke olakino cardiovascular
ʻO Telmisartan ʻoi aku ka maikaʻi o ka antihypertensive pale i ka renal

ʻO Telmisartan ʻoi aku ka maikaʻi o ka antihypertensive pale i ka renal
ʻO Flumazenil He Antagonist Receptor GABAA koho a me kāna mau noi Therapeutic

ʻO Flumazenil He Antagonist Receptor GABAA koho a me kāna mau noi Therapeutic
ʻO Trametinib Kinase Inhibitor e hoʻopaʻa ana i nā maʻi maʻi maʻi maʻi maʻi maʻi hoʻololi ʻana i ka BRAF V600

ʻO Trametinib Kinase Inhibitor e hoʻopaʻa ana i nā maʻi maʻi maʻi maʻi maʻi maʻi hoʻololi ʻana o BRAF V600
ʻO Dabrafenib He lāʻau lapaʻau i koho ʻia no nā maʻi maʻi maʻi BRAF-mutated

ʻO Dabrafenib kahi lāʻau lapaʻau i koho ʻia no nā maʻi maʻi maʻi BRAF-mutated
ʻO Tirzepatide Dual GLP-1 a me GIP Receptor Agonist no ka hoʻokele paona a me ka mana Glycemic

ʻO Tirzepatide Dual GLP-1 a me GIP Receptor Agonist no ka hoʻokele kaumaha a me ka mana Glycemic
ʻO Cisapride Gastric Stimulant no ka ʻai ʻana a me nā maʻi ʻeha

ʻO Cisapride Gastric Stimulant no nā maʻi ʻeha a me nā maʻi ʻai
YK-11 Potent SARM no ke kūkulu ʻana i nā ʻiʻo, nā loaʻa ikaika, a me ka pale ʻana i ka Myostatin.

YK-11 SARM ikaika no ke kūkulu ʻana i nā ʻiʻo, nā loaʻa ikaika, a me ka pale ʻana i ka Myostatin.
Ostarine (MK-2866) SARM maʻamau no ka ulu ʻana o ka ʻiʻo, ka momona momona, a me ka hoʻoponopono hou ʻana o ke kino.

ʻO Ostarine (MK-2866) SARM maʻamau no ka ulu ʻana o ka ʻiʻo, ka momona momona, a me ka hana hou ʻana o ke kino.
MK-677 Hui Kūʻokoʻa no ka ulu ʻana o ka ʻiʻo, hoʻomanawanui, a me ka hoʻihoʻi hou ʻana

MK-677 Hui Kūʻokoʻa no ka ulu ʻana o ka ʻiʻo, hoʻomanawanui, a me ka hoʻihoʻi hou ʻana
0102030405
ʻO Trametinib Kinase Inhibitor e hoʻopaʻa ana i nā maʻi maʻi maʻi maʻi maʻi maʻi hoʻololi ʻana i ka BRAF V600
ʻO Trametinib Kinase Inhibitor e hoʻopaʻa ana i nā maʻi maʻi maʻi maʻi maʻi maʻi hoʻololi ʻana i ka BRAF V600

ʻO Trametinib Kinase Inhibitor e hoʻopaʻa ana i nā maʻi maʻi maʻi maʻi maʻi maʻi hoʻololi ʻana o BRAF V600

Kumukuai kuhikuhi: USD 8-15/g

  • inoa mea kūʻai ʻO Trametinib
  • CAS No. 871700-17-3
  • MF C26H23FIN5O4
  • MW 615.402623
  • ʻO ka mānoanoa 1.743
  • Lae hehee 293-303°C
Kāhea iā mā˚ou
nā kikoʻī huahana

Ka wehewehe kikoʻī

ʻO Trametinib kahi mea hoʻopaneʻe kinase ikaika a koho i hoʻohana mua ʻia i ka mālama ʻana i ka melanoma unreectable a i ʻole metastatic me ka BRAF V600 mutation, a me nā ʻano kikoʻī o ka maʻi maʻi ʻaʻai kino liʻiliʻi a i ʻole metastatic. Ke ʻimi nei kēia ʻatikala i ke ʻano o ka hana, nā hōʻailona lapaʻau, a me nā pōmaikaʻi o ka trametinib i ka mālama ʻana i nā maʻi maʻi maʻi maʻi BRAF V600.

I. Ka hoomaopopo ana i ka Trametinib:
A. Oral, potent, and selective kinase inhibitor
ʻO B. No ka papa mea hoʻopaneʻe MEK
C. Hoʻopaʻa i ka hana kinase o MEK1 a me MEK2
D. Kāohi i lalo o ERK1 a me ERK2 hōʻailona

II. Nā hōʻailona hōʻailona:
A. ʻO ka melanoma hiki ʻole ke wehe ʻia a i ʻole ka metastatic melanoma e mālama ana i ka hoʻololi BRAF V600:
ʻO ka hui pū ʻana me ka dabrafenib mesylate
B. ʻO ka lāʻau kōkua ma hope o ka hana ʻana no ka BRAF V600 mutation-positive melanoma:
ʻO ka lāʻau adjuvant me ka dabrafenib mesylate ma hope o ka wehe ʻana

17161152266097be

III. Ke kuleana ma ka maʻi maʻi maʻi ʻaʻole liʻiliʻi.

A. ʻAʻole liʻiliʻi liʻiliʻi pūlaʻi maʻi 'aʻai maʻi 'o ke kumu nui o ka maʻi a me ka make

B. BRAF gene mutation rate and prevalence of BRAF V600E mutation

C. ʻO ka hopena pale o Trametinib ma BRAF V600 mutation-positive melanoma cell


IV. Mechanism o ka hana:

A. Hiki ke ho'ololi 'ia o ka mitogen-activated extracellular signal-regulated kinase (MEK) 1 a me MEK2

B. Ka hopena ma ke ala MAPK a me ka protein MEK

C. Ka hoʻopaʻa ʻana i ka hoʻonui ʻana o ke kelepona a me ke ala ERK i lalo


V. ʻO ka lāʻau lapaʻau ma hope o ka hana ʻana:

A. Nā pōmaikaʻi o ka lāʻau lapaʻau i manaʻo ʻia me Dabrafenib a me Trametinib

B. Nā pōmaikaʻi no ka wā lōʻihi a me ka hoʻihoʻi hou ʻole ʻia (RFS) i ka pae kiʻekiʻe o ka pae III BRAF mutation-positive melanoma maʻi.



ʻO Trametinib, kahi mea hoʻopaneʻe kinase i manaʻo ʻia, e hōʻike ana i ka maikaʻi nui i ka mālama ʻana i nā maʻi maʻi maʻi maʻi maʻi maʻi BRAF V600, ʻoi aku ka maʻi maʻi unresectable a i ʻole metastatic melanoma a me nā ʻano kikoʻī o ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi. ʻO kāna hana o ka hana, ke kāohi ʻana i ka hana MEK1 a me MEK2 kinase, ke alakaʻi i ke ala ERK ala i lalo a me ka hoʻopau ʻana i ka hoʻonui ʻana o ka cell. ʻO Trametinib, i hui pū ʻia me ka dabrafenib mesylate, hāʻawi i nā pōmaikaʻi therapeutic i nā hoʻonohonoho kiʻekiʻe a me ka adjuvant no nā maʻi melanoma mutation-positive BRAF V600.
E hoʻokaʻaʻike mai iā mākou no ka ʻōlelo aʻoaʻo lāʻau a me ka ʻike kumu kūʻai nui e hoʻomaikaʻi i ka mālama maʻi.

Hōʻike

171611254334271z